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Abstract
Background Mild biventricular dysfunction is often present
in patients with Marfan syndrome. Losartan has been
shown to reduce aortic dilatation in patients with Mar-
fan syndrome. This study assesses the effect of losartan
on ventricular volume and function in genetically classi-
fied subgroups of asymptomatic Marfan patients without
significant valvular regurgitation.
Methods In this predefined substudy of the COMPARE
study, Marfan patients were classified based on the effect
of their FBN1 mutation on fibrillin-1 protein, categorised
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as haploinsufficient or dominant negative. Patients were
randomised to a daily dose of losartan 100 mg or no ad-
ditional treatment. Ventricular volumes and function were
measured by magnetic resonance imaging at baseline and
after 3 years of follow-up.
Results Changes in biventricular dimensions were as-
sessed in 163 Marfan patients (48 % female; mean age
38 ± 13 years). In patients with a haploinsufficient FBN1
mutation (n = 43), losartan therapy (n = 19) increased
both biventricular end diastolic volume (EDV) and stroke
volume (SV) when compared with no additional losartan
(n = 24): left ventricular EDV: 9 ± 26 ml vs. –8 ± 24 ml,
p = 0.035 and right ventricular EDV 12 ± 23 ml vs. –18 ±
24 ml; p < 0.001 and for left ventricle SV: 6 ± 16 ml vs.
–8 ± 17 ml; p = 0.009 and right ventricle SV: 8 ± 16 ml vs.
–7 ± 19 ml; p = 0.009, respectively. No effect was observed
in patients with a dominant negative FBN1 mutation (n =
92), or without an FBN1 mutation (n = 28).
Conclusion Losartan therapy in haploinsufficient Marfan
patients increases biventricular end diastolic volume and
stroke volume, furthermore, losartan also appears to ame-
liorate biventricular filling properties.
Keywords Marfan syndrome · Ventricular function ·
Ventricular volumes · Losartan · Cardiac magnetic
resonance imaging · FBN1 mutation classes
Introduction
Marfan syndrome (MFS) is caused by mutations in the
FBN1 gene, leading to deficiency (haploinsufficient {HI}
mutations) or malformation (dominant-negative {DN} mu-
tations) of the fibrillin-1 protein [1], ultimately leading to
aortic dilatation and dissection [2–4]. Treatment with losar-
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tan, an angiotensin-II receptor-1 blocker (ARB), has been
shown to have a beneficial effect on aortic pathology in
MFS murine models. Human MFS studies on aortic di-
latation rate have demonstrated conflicting results [5–7],
however, losartan may have a beneficial effect in patients
with an HI mutation.
Although a mild biventricular dysfunction is often
present in MFS patients without significant valvular pathol-
ogy [8–12], the effect of losartan on cardiac dimensions
and function in MFS patients is still unknown. Here, we
assess the effect of losartan on left and right ventricular
dimensions and function in both HI and DN asymptomatic
MFS patients without significant valvular regurgitation by
cardiac magnetic resonance imaging (CMR).
Methods
Patients
All study subjects were participants in the multicentre, ran-
domised COMPARE trial [5, 13]. In short, the COMPARE
trial was designed to investigate the effect of losartan on
the aortic dilatation rate in adult MFS patients. Patients
(≥18 years) fulfilling the Ghent criteria of 1996 were in-
cluded [14]. Exclusion criteria were: (A) treatment with
angiotensin-converting-enzyme inhibitor (ACEi) or ARB
before study entry, (B) an aortic root diameter >50 mm,
(C) a history of aortic dissection, and (D) ≥1 vascular pros-
thesis. For the current predefined study, (E) only patients
fulfilling the revised Ghent criteria of 2010 [15] were in-
cluded, and (F) patients with moderate to severe valvu-
lar regurgitation were excluded [16]. All previously pre-
scribed medication, including β-blockers and calcium chan-
nel blockers, was continued during the study. Written in-
formed consent was obtained from all participants. The
study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki and was approved by the in-
stitution’s human research committee. All patients gave
their informed consent.
Mutation classification
To detect mutations, sanger sequencing of the 65 coding
FBN1 exons in genomic DNA was used. Mutations were
classified into two groups according to the effect of the
mutation on the fibrillin-1 protein [17]. Patients with a DN
effect were defined as having mutations leading to pro-
duction of malfunctional fibrillin-1 protein. DN mutations
included: (1) missense mutations leading to stable mutant
fibrillin-1 protein; (2) mutations leading to exon skipping
or deletion resulting in in-frame events [18]; and (3) prema-
ture termination codon mutations leading to a shorter but
stable fibrillin-1 protein (>10 exons).
An HI effect of the FBN1 mutation was defined as a mu-
tation leading to a reduced amount of normal fibrillin-1
protein [19–21] as predicted by the Alamut® software (In-
teractive Biosoftware, Rouen, France) [21]. HI mutations
included: (1) deletion of the whole FBN1 gene; (2) deletion
of at least the first or last exon; (3) premature termination
codon mutations leading to nonsense mediated decay or to
a very short truncated protein (translation <10 exons of the
FBN1 gene) [22]; and (4) missense mutations leading to
degradation of the protein [23].
Medication
Participating patients started on losartan treatment after
baseline examinations. Patients were randomly assigned
to a 1:1 ratio to receive losartan daily (losartan group), or
to no additional treatment (control group). Target dosage
was 100 mg losartan daily.
Magnetic resonance imaging
At baseline and after 3 years of follow-up, CMR imaging
of the right and left ventricle was performed. All CMR
scans were performed at two centres (Academic Medical
Center Amsterdam and Leiden University Medical Center).
To obtain ventricular volumes, magnetic resonance imaging
was performed with either an Avanto (Siemens, Erlangen,
Germany), or a Philips (Intera, release 11 and 12; Philips
Medical Systems, Best, the Netherlands) 1.5 T MRI scan-
ner using a phased array cardiac receiver coil. ECG-gated
cine images were acquired during breath-hold using a seg-
mented, steady-state, free-precession sequence. Short-axis
views were obtained every 10 mm, starting from the base
up to the apex and covering the entirety of both ventricles.
Additionally, flow (m/s) through the aortic root and ascend-
ing aorta was assessed by phase contrast velocity mapping
to rule out significant valvular regurgitation, unnoticed at
prior echocardiography.
Image analysis
The primary endpoint of this study was change in left and
right ventricular volumes and systolic function after 3 years
of follow-up measured by CMR. All measurements were
performed using MASS® and FLOW® image analysis soft-
ware (Medis, Leiden, the Netherlands) by a single observer
(AWdH) under the supervision of an experienced cardiolo-
gist (MG) and radiologist (AMS) with no prior knowledge
of patients’ medical therapy.
Endocardial contours of the left and right ventricle were
manually traced in end systole and end diastole on all short-
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204 patients with adequate baseline
ventricular CMR
104 patients were assigned to
Losartan group
100 patients were assigned to
Control group
27 patients exluded due to:
17 Discontinued losartan treatment
2 Valve regurgitation
8 FU CMR not performed or incomplete
77 patients in
ventricular analysis
86 patients in
ventricular analysis
14 patients excluded due to:
1 Started on losartan treatment
13 FU CMR not performed or
incomplete
233 patients in Compare trial
29 patients excluded due to
6 mutations other than FBN1
23 Baseline CMR incomplete
Fig. 1 Randomisation and follow-up for ventricular function analysis. Abbreviations: CMR denotes cardiac magnetic resonance, FU denotes
follow-up
axis images. End diastole was defined as the phase with the
largest ventricular area and end systole as the phase with
the smallest ventricular area. Left ventricular (LV) and right
ventricular (RV) end diastolic volume (EDV), end systolic
volume (ESV) and stroke volume (SV = EDV-ESV) were
determined. Left and right ventricular ejection fraction (EF)
was calculated (EF = SV/EDV). Flow through the aorta
was calculated using manually drawn areas on the mod-
ulus images and the velocity values of the corresponding
velocity encoded images by using flow image analysis soft-
ware (Flow®, Medis, Leiden, the Netherlands). Severity of
valvular regurgitation was assessed quantitatively by CMR
in accordance with ACC/AHH guidelines for the manage-
ment of patients with valvular heart disease [16]. Moderate
to severe valvular regurgitation was defined as regurgitant
volume of ≥30 ml per beat or a regurgitant fraction of ≥30 %
[16]. a dilated ventricle was assumed to exceed an EDV of
97 ml/m2 [24].
Statistical analysis
Data are presented as mean value ± standard deviation
and categorical variables as numbers and percentages. Be-
tween-group comparisons of quantitative and categorical
variables were made by Students’ t-test and Fisher’s ex-
act tests, respectively. Associations between characteris-
tics were explored with regression analysis. The effect of
losartan on change in ventricular volumes and function was
evaluated by the two-tailed Student’s t-tests. All analyses
were per protocol analyses in order to evaluate the change
in ventricular volumes between the two groups of MFS
patients who continued their losartan treatment throughout
the entire study, and those in whom losartan treatment was
not started during the study. a two-tailed P < 0.05 was
considered statistically significant. For statistical analyses,
PASW 19.0 (SPSS Inc., Chicago, IL) for Windows (Mi-
crosoft, Redmond, WA) was used.
Results
Patients
Patient recruitment and characteristics have been described
in detail previously [5]. (17)In the COMPARE trial, a to-
tal of 233 MFS patients were included between January
678 Neth Heart J (2016) 24:675–681
2008 and December 2009 [5]. Change in cardiac func-
tion was assessed in 163 patients (48 % female, mean age
38 ± 13 years, Fig. 1). a pathogenic FBN1 mutation was
found in 135 patients (83 %). In patients with a known
FBN1 mutation, 92 patients (68 %) had a DN FBN1 mu-
tation and 43 patients (32 %) had an HI FBN1 mutation.
No FBN1 mutation could be found in 28 patients. a total
of 77 MFS patients were randomised to losartan treatment,
while 86 MFS patients received no additional treatment.
The remaining cardiovascular medicinal treatment did not
change during follow-up.
Baseline characteristics between the treatment groups
were comparable with the exception of body surface area
(BSA) and heart rate in HI patients (Table 1).
Left ventricular EF in DN patients was lower than the
EF in HI patients, 51 ± 7 % vs. 53 ± 4 %, p = 0.013.
The remaining ventricular characteristics were comparable
Table 1 Baseline characteristics of 163 patients with Marfan syndrome
Characteristics Losartan No losartan
No FBN1 DN HI No FBN1 DN HI
Number of patients 16 42 19 12 50 24
Age (years) 39 ± 13 36 ± 12 33 ± 10 44 ± 12 39 ± 14 37 ± 13
Male (%) 9 (56) 23 (55) 10 (53) 6 (50) 24 (48) 13 (54)
BSA (m2) 2.0 ± 0.2 2.0 ± 0.2 2.0 ± 0.2* 1.9 ± 0.4 2.0 ± 0.2 2.1 ± 0.2*
MAP (mm Hg) 93 ± 13 91 ± 11 91 ± 11 87 ± 13 90 ± 9 90 ± 8
Heartrate (bpm) 67 ± 11 68 ± 13 67 ± 14* 68 ± 15 66 ± 11 61 ± 6*
Aortic root diameter (mm) 45 ± 6 44 ± 5 44 ± 6 42 ± 3 45 ± 5 43 ± 5
Aortic root replacement (%) 4 (25) 6 (14) 5 (26) 7 (58) 16 (32) 5 (21)
Mitral valve surgery (%) 1 (6) 0 0 0 4 (8) 0
Valve dysfunction
≥ moderate AR (%) 0 0 1 (3) 0 0 0
≥ moderate MR (%) 0 0 1 (3) 0 0 0
≥ moderate TR (%) 0 0 0 0 0 0
≥ moderate PR (%) 0 0 0 0 0 0
Medication
β-blocker use (%) 13 (81) 31 (74) 14 (74) 9 (75) 36 (72) 14 (58)
Left Ventricular
ESV/BSA (ml/m2) 39 ± 9 42 ± 11 42 ± 10 44 ± 13 44 ± 14 39 ± 9
EDV/BSA (ml/m2) 81 ± 14 86 ± 18 87 ± 17 89 ± 19 88 ± 18 86 ± 15
SV/BSA (ml/m2) 43 ± 8 44 ± 10 45 ± 9 45 ± 8 44 ± 7 46 ± 8
EF (%) 53 ± 7 51 ± 6 52 ± 4 52 ± 6 50 ± 7 54 ± 5
Right Ventricular
ESV/BSA (ml/m2) 45 ± 12 40 ± 12 41 ± 10 43 ± 11 42 ± 16 40 ± 10
EDV/BSA (ml/m2) 86 ± 19 82 ± 18 83 ± 14 86 ± 18 84 ± 19 85 ± 13
SV/BSA (ml/m2) 41 ± 9 42 ± 8 42 ± 7 43 ± 9 42 ± 7 45 ± 7
EF (%) 48 ± 5 52 ± 7 51 ± 5 50 ± 6 51 ± 8 53 ± 7
BSA Body Surface Area, MAP Mean Arterial Pressure, AR Aortic Regurgitation, MR Mitral Regurgitation, TR Tricuspid Regurgitation, PR Pul-
monary Regurgitation, ESV End Systolic Volume, EDV End Diastolic Volume, SV Stroke Volume, EF Ejection Fraction, CI Cardiac Index,
DN Dominant Negative FBN1 mutation, HI Haploinsufficient FBN1 mutation
Plus-minus values are means ± SD
*p < 0.005 for BSA and Heartrate in HI patients between treatment groups
between the groups, including the frequency of a dilated
ventricle 26 % vs. 23 %, p = 0.724, respectively.
Losartan and ventricular function in mutational
subgroups
After a mean of 3.1 ± 0.4 years of follow-up, the biven-
tricular EDV increased in HI patients on losartan therapy
(n = 19) compared with HI controls (n = 24): LV-EDV: 9 ±
26 ml vs. –8 ± 24 ml; p = 0.035 and RV-EDV 12 ± 23 ml vs.
–18 ± 24 ml; p < 0.001, respectively. Similar results were
seen in RV-ESV, however, not in LV-ESV (Table 2). In HI
patients on losartan therapy, the increase in biventricular
EDV was accompanied by an increase in SV, for LV-SV:
6 ± 16 ml vs. –8 ± 17 ml; p = 0.009 and RV-SV: 8 ± 16 ml
vs. –7 ± 19 ml; p = 0.009, respectively (Table 2, Fig. 2). No
effect of losartan was observed in patients with a DN FBN1
mutation or without an FBN1 mutation. No effect of losar-
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Table 2 The effect of losartan on left and right ventricle volume and function in Marfan patients with a FBN1 mutation leading to haploinsuffi-
ciency or a dominant-negative effect during 3 years of follow-up
Haploinsufficiency Dominant Negative
Losartan No losartan p-value Losartan No losartan p-value
Number of patients 19 24 – 42 50 –
 MAP (mm Hg) –3 ± 8 –4 ± 9 0.684 –8 ± 10 –2 ± 8 0.003
 HR (bpm) 3 ± 16 4 ± 23 0.950 0 ± 21 3 ± 15 0.442
 Left Ventricular
ESV (ml) 3 ± 16 0 ± 15 0.537 4 ± 22 2 ± 22 0.696
EDV (ml) 9 ± 26 –8 ± 24 0.035 3 ± 33 0 ± 29 0.637
SV (ml) 6 ± 16 –8 ± 17 0.009 –1 ± 19 –2 ± 16 0.725
EF (%) 1 ± 5 –2 ± 6 0.157 –1 ± 6 –1 ± 7 0.770
 Right Ventricular
ESV (ml) 4 ± 20 –12 ± 13 0.004 –1 ± 22 –8 ± 27 0.116
EDV (ml) 12 ± 23 –18 ± 24 <0.001 0 ± 31 –8 ± 27 0.223
SV (ml) 8 ± 16 –7 ± 19 0.009 1 ± 17 0 ± 17 0.820
EF (%) 1 ± 7 1 ± 7 0.889 1 ± 7 2 ± 7 0.418
MAP Mean Arterial Pressure, HR Heartrate, ESV End Systolic Volume, EDV End Diastolic Volume, SV Stroke Volume, EF Ejection Fraction
Plus-minus values are means ± SD
tan on mean arterial blood pressure (MAP) was observed
in HI patients.
Changes in left and right ventricular volumes and func-
tion in the entire cohort were comparable between the losar-
tan group and the control group. Furthermore, analysis
of losartan only therapy or a combination of losartan and
β-blocker therapy on right or left ventricular volumes, heart
rate or EF in this subgroup rendered similar results.
Blood pressure and ventricular function
In the entire cohort, after 3 year’s treatment losartan signif-
icantly reduced MAP by 7 ± 10 mm Hg when compared
with baseline (p < 0.001), and differed significantly from
change in MAP compared with the control group. At base-
line, no significant correlation was found between MAP
and ESV, EDV or SV (r = 0.064, p = 0.426; r = –0.014,
p = 0.860; r = –0.108, p = 0.176; respectively). In losartan
treated patients, there was also no significant correlation
between change in MAP and change in ESV, EDV or SV
(r = –0.117, p = 0.326; r = –0.060, p = 0.615; r = 0.023,
p = 0.847; respectively).
Discussion
To our knowledge, this is the first large follow-up study
to assess the effect of losartan on biventricular function in
both HI and DN asymptomatic MFS patients using CMR.
In this study, LV-EF was lower in MFS patients with a DN
FBN1 mutation than in those with an HI FBN1 mutation.
Losartan therapy increased EDV and SV, independent of
change in blood pressure only in MFS patients with an
HI FBN1 mutation. Furthermore, no beneficial effect of
losartan on cardiac systolic function in the study group as
a whole could be demonstrated.
MFS is caused by mutations in the FBN1 gene, leading to
HI or DN mutations of the fibrillin-1 protein [1]. Both mu-
tations indirectly lead to increased levels of TGF-β, which
is correlated to aortic disease in MFS [17]. However, TGF-
β most likely also plays a role in myocardial fibrosis [25,
26]. Furthermore, blocking of TGF-β in both rat studies
involving pressure-overloaded hearts and mice studies in-
volving hypertrophic hearts, prevented myocardial fibrosis
and diastolic dysfunction [27–29].
Losartan, an angiotensin II receptor type 1 inhibitor, is
known to reduce both TGF-β signalling and blood pressure.
However, we demonstrated that (change of) mean arterial
blood pressure did not correlate with (change in) ventricular
dimensions. Therefore, the effect of losartan on ventricular
dimensions is not merely blood pressure-related. a possible
explanation for the significant difference in baseline ven-
tricular function and response to losartan between HI and
DN might therefore be due to a difference in TGF-β levels.
This is in line with an earlier study by Franken et al., who
demonstrated that losartan therapy significantly reduced the
aortic root dilatation rate in the HI, whereas only a mod-
est, insignificant reduction was found in DN MFS patients
[17]. Furthermore, HI patients have a reduced but function-
ally normal fibrillin-1 protein, while the DN patient group
is more heterogeneous since they display a broad spectrum
of dysfunctional fibrillin-1 proteins, possibly explaining the
variable response to losartan in the DN group. In addition,
reduced ventricular function in DN patients might also be
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Fig. 2 Box plot showing
change in left and right ven-
tricular stroke volume between
control and losartan group in
Marfan patients with a FBN1
mutation leading to haploinsuffi-
ciency (n = 43) or to a dominan-
t-negative effect (n = 92). Ab-
breviations: SV denotes stroke
volume, LV denotes left ventri-
cle, RV denotes right ventricle.
Boxes indicate median with in-
terquartile range. Error bars
indicate upper 90 percentile and
lower 10 percentile limits
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the result of a disorganised ECM due to the dysfunctional
fibrillin-1 proteins [30, 31].
In conclusion, systolic ventricular function in MFS pa-
tients with a DN FBN1 mutation was slightly, but signif-
icantly reduced compared with patients with an HI FBN1
mutation. In MFS patients with an FBN1 mutation leading
to HI, losartan increased both EDV and SV, independent of
change in blood pressure, suggesting a beneficial effect on
left and right ventricular filling properties. No beneficial
effect of losartan on ventricular function in the entire MFS
cohort could be demonstrated.
Limitations
Our patients were still relatively young and mainly asymp-
tomatic. Furthermore, the clinical implications of our find-
ings are limited. However, the occurrence of ventricu-
lar dysfunction will most likely increase due prolonged
longevity in MFS as a result of prophylactic aortic root
replacement and improved medicinal therapy. Other lim-
itations are the limited sample size, lack of TGF-β levels
and relatively small subgroups. Although losartan appeared
to increase EDV in HI patients, thereby suggesting a ben-
eficial effect on left and right ventricular filling properties,
absolute diastolic filling properties were not assessed by
CMR.
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